🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  2. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    4 trials

  3. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    REM Behavior Disorder

    phase 1 small molecule terminated

    1 trial

  4. Tasimelteon Oral Capsule

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  5. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Relapsed or Refractory Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  6. VHX-896

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  7. VHX-896 and iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  8. VHX-896 and iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  9. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Pruritus

    phase 1 small molecule completed

    1 trial

  10. Vagal Nerve Stimulation

    Rhythm Pharmaceuticals Netherlands B.V.

    Inflammation

    phase 1 other completed

    1 trial

  11. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  12. Z-1018

    Dynavax International B.V.

    Shingles

    phase 1 mab completed

    1 trial

  13. [14C]-AG-120

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  14. [14C]-tebapivat

    Agios Netherlands B.V.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  15. givosiran (ALN-AS1)

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 1 small molecule completed

    1 trial

  16. iloperidone (oral tablet)

    Vanda Pharmaceuticals Netherlands B.V.

    Safety and Tolerability of Iloperidone

    phase 1 small molecule completed

    1 trial

  17. itraconazole

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. ivosidenib (AG-120)

    Agios Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  19. locally manufactured adoptive cellular therapy (ACT) product

    Iovance Biotherapeutics B.V.

    Malignant Pleural Effusion

    phase 1 mab active

    1 trial

  20. patisiran

    Alnylam Netherlands B.V.

    Polyneuropathies

    phase 1 small molecule completed

    1 trial

  21. patisiran (ALN-TTR02)

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  22. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Circadian Rhythm Sleep Disorders

    phase 1 small molecule completed

    1 trial

  23. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  24. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources